Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.ALRN · Entity 7071 | SVP, Research | March 30, 2022 | March 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date March 30, 2022 · Filed March 30, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2032-03-29 | Direct | 313,000 |
Reported balance
After 2022-03-30 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-30 · Grant · Acquired 313,000 · Balance 313,000 F1: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022. F2: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022.
F2: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2022 Filed Mar 30, 2022 20:31 UTC Amendment | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 313,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-22-012855 · doc4a.xml · derivative · entry 1 Annis Allen · CIK 0001709601 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,000 Underlying: Common Stock · 313,000 shares Expires 2032-03-29 F1 · date: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 19:45 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 313,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-012149 · doc4.xml · derivative · entry 1 Annis Allen · CIK 0001709601 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,000 Underlying: Common Stock · 313,000 shares Expires 2032-03-21 F1 · derivative.exercise_date: This option was granted on March 22, 2022. The shares underlying the option are scheduled to vest in equal monthly installments through March 22, 2026. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 19:49 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 474,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024521 · doc4.xml · derivative · entry 1 Annis Allen · CIK 0001709601 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,000 Underlying: Common Stock · 474,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest as to 25% of the shares on June 15, 2022 and thereafter in equal monthly installments through June 15, 2025. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:33 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-20-002808 · doc4.xml · derivative · entry 1 Annis Allen · CIK 0001709601 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: This option was granted on January 31, 2020. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 31, 2020. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 18:41 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-19-010812 · doc4.xml · derivative · entry 1 Annis Allen · CIK 0001709601 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.